Anti-angiogenic therapies are thus being evaluated in early phase paediatric clinical trials, such as the BEACON trial in which the VEGF-A inhibitor bevacizumab was shown to have activity in neuroblastoma [10]. This evidence concerns the gene VEGFA and neuroblastoma.